OTCM
HYPMY
Market cap3.83bUSD
Oct 07, Last price
5.40USD
1D
0.84%
1Q
36.25%
Jan 2017
-31.70%
IPO
-60.14%
Name
Hypera SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Key people
Alvado Stainfeld Link
Chairman of the Board · since 2019
Breno Toledo De Oliveira
Chief Executive Officer · since 2023
Ramon Sanches Frutuoso Silva
Chief Financial Officer · since 2021
Juliana Aguinaga Damiao Salem
Executive Officer - Legal Department · since 2024
Rafael Vito Batista
Executive Officer · since 2025
Adalmario Do Couto
Investor Relations Officer, Business Development Officer · since 2022
Luciana Cavalheiro De Queiroz
Member of the Board of Directors · since 2007
Member of the Board of Directors · since 2007
Bernardo Malpica Hernandez
Member of the Board of Directors · since 2007
Hugo Barreto Sodre Leal
Member of the Board of Directors · since 2019
Mauro Gentile Rodrigues Da Cunha
Independent Member of the Board of Directors · since 2023
Eliana Helena De Gregorio Ambrosio
Independent Member of the Board of Directors · since 2023
Independent Member of the Board of Directors · since 2017
Flair Jose Carrilho
Independent Member of the Board of Directors · since 2019
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||